|
1
|
Krivoy A, Fischel T and Weizman A: The
cognitive deficit in schizophrenia. Harefuah. 151:277–280, 319.
2012.(In Hebrew). PubMed/NCBI
|
|
2
|
McGurk SR, Mueser KT, Covell NH, Cicerone
KD, Drake RE, Silverstein SM, Medialia A, Myers R, Bellack AS, Bell
MD, et al: Mental health system funding of cognitive enhancement
interventions for schizophrenia: Summary and update of the New York
Office of Mental Health expert panel and stakeholder meeting.
Psychiatr Rehabil J. 36:133–145. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kim SY, Lee H, Kim HJ, Bang E, Lee SH, Lee
DW, Woo DC, Choi CB, Hong KS, Lee C, et al: In vivo and ex vivo
evidence for ketamine-induced hyperglutamatergic activity in the
cerebral cortex of the rat: Potential relevance to schizophrenia.
NMR Biomed. 24:1235–1242. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zimnisky R, Chang G, Gyertyán I, Kiss B,
Adham N and Schmauss C: Cariprazine, a dopamine
D(3)-receptor-preferring partial agonist, blocks
phencyclidine-induced impairments of working memory, attention
set-shifting, and recognition memory in the mouse.
Psychopharmacology (Berl). 226:91–100. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ihalainen J, Savolainen K, Tanila H and
Forsberg MM: Comparison of phencyclidine-induced spatial learning
and memory deficits and reversal by sertindole and risperidone
between Lister Hooded and Wistar rats. Behav Brain Res.
305:140–147. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gopalakrishna G, Ithman MH and Lauriello
J: Update on New and Emerging Treatments for Schizophrenia.
Psychiatr Clin North Am. 39:217–238. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Amr M, Lakhan SE, Sanhan S, Al-Rhaddad D,
Hassan M, Thiabh M and Shams T: Efficacy and tolerability of
quetiapine versus haloperidol in first-episode schizophrenia: A
randomized clinical trial. Int Arch Med. 6:472013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tuplin EW, Stocco MR and Holahan MR:
Attenuation of MK-801-induced behavioral perseveration by typical
and atypical antipsychotic pretreatment in rats. Behav Neurosci.
129:399–411. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mutlu O, Ulak G, Celikyurt IK, Akar FY,
Erden F and Tanyeri P: Effects of olanzapine, sertindole and
clozapine on MK-801 induced visual memory deficits in mice.
Pharmacol Biochem Behav. 99:557–565. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Skarsfeldt T: Differential effect of
antipsychotics on place navigation of rats in the Morris water
maze. A comparative study between novel and reference
antipsychotics. Psychopharmacology (Berl). 124:126–133. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bourin M, Chenu F, Prica C and Hascoët M:
Augmentation effect of combination therapy of aripiprazole and
antidepressants on forced swimming test in mice. Psychopharmacology
(Berl). 206:97–107. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bunsey M and Eichenbaum H: Selective
damage to the hippocampal region blocks long-term retention of a
natural and nonspatial stimulus-stimulus association. Hippocampus.
5:546–556. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lally J and MacCabe JH: Antipsychotic
medication in schizophrenia: A review. Br Med Bull. 114:169–179.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kumari V, Ettinger U, Lee SE, Deuschl C,
Anilkumar AP, Schmechtig A, Corr PJ, Ffytche DH and Williams SC:
Common and distinct neural effects of risperidone and olanzapine
during procedural learning in schizophrenia: A randomised
longitudinal fMRI study. Psychopharmacology (Berl). 232:3135–3147.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mutlu O, Ulak G, Celikyurt IK, Akar FY and
Erden F: Effects of olanzapine, sertindole and clozapine on
learning and memory in the Morris water maze test in naive and
MK-801-treated mice. Pharmacol Biochem Behav. 98:398–404. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Buoli M, Kahn RS, Serati M, Altamura AC
and Cahn W: Haloperidol versus second-generation antipsychotics in
the long-term treatment of schizophrenia. Hum Psychopharmacol.
31:325–331. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tadori Y, Forbes RA, McQuade RD and
Kikuchi T: In vitro pharmacology of aripiprazole, its metabolite
and experimental dopamine partial agonists at human dopamine D2 and
D3 receptors. Eur J Pharmacol. 668:355–365. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Topolov MK and Getova DP: Cognitive
Impairment in Schizophrenia, Neurotransmitters and the New Atypical
Antipsychotic Aripiprazole. Folia Med (Plovdiv). 58:12–18.
2016.PubMed/NCBI
|
|
19
|
de Bartolomeis A, Buonaguro EF and
Iasevoli F: Serotonin-glutamate and serotonin-dopamine reciprocal
interactions as putative molecular targets for novel antipsychotic
treatments: From receptor heterodimers to postsynaptic scaffolding
and effector proteins. Psychopharmacology (Berl). 225:1–19. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Eggers AE: A serotonin hypothesis of
schizophrenia. Med Hypotheses. 80:791–794. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dall'Olio R, Gandolfi O and Gaggi R:
Blockade of the serotonergic system counteracts the
dizocilpine-induced changes in dopaminergic function. Behav
Pharmacol. 11:29–36. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Meltzer HY, Rajagopal L, Huang M, Oyamada
Y, Kwon S and Horiguchi M: Translating the N-methyl-D-aspartate
receptor antagonist model of schizophrenia to treatments for
cognitive impairment in schizophrenia. Int J Neuropsychopharmacol.
16:2181–2194. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Talpos J, Aerts N, Waddell J and Steckler
T: MK-801 and amphetamine result in dissociable profiles of
cognitive impairment in a rodent paired associates learning task
with relevance for schizophrenia. Psychopharmacology (Berl).
232:3911–3920. 2015. View Article : Google Scholar : PubMed/NCBI
|
